Targeting RPL39 and MLF2 reduces tumor initiation and metastasis in breast cancer by inhibiting nitric oxide synthase signaling

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 24, 2014, Pages 8838-8843

  Dave, Bhuvanesh ^a   Granados Principal, Sergio ^a   Zhu, Rui ^a   Benz, Stephen ^b   Rabizadeh, Shahrooz ^c   Soon Shiong, Patrick ^c   Yu, Ke Da ^d   Shao, Zhimin ^d   Li, Xiaoxian ^e   Gilcrease, Michael ^e   Lai, Zhao ^f   Chen, Yidong ^f   Huang, Tim H M ^f   Shen, Haifa ^a   Liu, Xuewu ^a   Ferrari, Mauro ^a   Zhan, Ming ^a   Wong, Stephen T C ^a   Kumaraswami, Muthiah ^a   Mittal, Vivek ^g   Chen, Xi ^g   Gross, Steven S ^g   Chang, Jenny C ^a   more..

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b Five3 Genomics   (United States)

^c Chan Soon Shiong Institute for Advanced Health   (United States)

^d FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; NANOPARTICLE; NITRIC OXIDE SYNTHASE; ONCOPROTEIN; PROTEIN MLF2; PROTEIN RPL39; RIBOSOME PROTEIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CANCER STEM CELL; CANCER PATIENT; CANCER STEM CELL; CELL RENEWAL; CELL SUBPOPULATION; CONTROLLED STUDY; DRUG TARGETING; GENE MUTATION; HUMAN; HUMAN CELL; HYPOXIA; LUNG METASTASIS; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; RNA SEQUENCE; SIGNAL TRANSDUCTION; TUMOR BIOPSY; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANOXIA; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LUNG NEOPLASMS; MICE; MICE, SCID; MUTATION; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NUCLEAR PROTEINS; RIBOSOMAL PROTEINS; RNA, SMALL INTERFERING; SEQUENCE ANALYSIS, RNA; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 84902590159     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1320769111     Document Type: Article

References (56)

1. Gerlinger M, et al. (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366(10):883-892.
2. Campbell PJ, et al. (2010) The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467(7319):1109-1113.
3. Campbell PJ, et al. (2008) Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat Genet 40(6):722-729. (Pubitemid 351748860)
4. Shah NP, et al. (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2(2):117-125. (Pubitemid 41039112)
5. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100(7):3983-3988. (Pubitemid 36418143)
6. Lapidot T, et al. (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367(6464):645-648. (Pubitemid 24067706)
7. Li X, et al. (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100(9):672-679.
8. Smalley M, Ashworth A (2003) Stem cells and breast cancer: A field in transit. Nat Rev Cancer 3(11):832-844. (Pubitemid 37376981)
9. Stingl J, Caldas C (2007) Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer 7(10):791 -799.
10. Chen J, et al. (2012) A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488(7412):522-526.
11. Driessens G, Beck B, Caauwe A, Simons BD, Blanpain C (2012) Defining the mode of tumour growth by clonal analysis. Nature 488(7412):527-530.
12. Schepers AG, et al. (2012) Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 337(6095):730-735.
13. Creighton CJ, Chang JC, Rosen JM (2010) Epithelial-mesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in breast cancer. J Mammary Gland Biol Neoplasia 15(2):253-260.
14. Jones RJ, Matsui WH, Smith BD (2004) Cancer stem cells: Are we missing the target? J Natl Cancer Inst 96(8):583-585. (Pubitemid 38584981)
15. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW (1997) Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38(2):285-289. (Pubitemid 27318643)
16. Hockel M, et al. (1996) Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56(19):4509-4515. (Pubitemid 26330463)
17. Nordsmark M, Overgaard M, Overgaard J (1996) Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 41(1):31-39. (Pubitemid 26396294)
18. Sundfør K, Lyng H, Rofstad EK (1998) Tumour hypoxia and vascular density as predictors of metastasis in squamous cell carcinoma of the uterine cervix. Br J Cancer 78(6):822-827. (Pubitemid 28418321)
19. Li Z, et al. (2009) Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 15(6):501-513.
20. Jensen RL (2009) Brain tumor hypoxia: Tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J Neurooncol 92(3):317-335.
21. Heddleston JM, et al. (2011) Glioma stem cell maintenance: The role of the microenvironment. Curr Pharm Des 17(23):2386-2401.
22. Creighton CJ, et al. (2009) Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 106(33): 13820-13825.
23. Gobeil S, Zhu X, Doillon CJ, Green MR (2008) A genome-wide shRNA screen identifies GAS1 as a novel melanoma metastasis suppressor gene. Genes Dev 22(21):2932-2940.
24. Kessler JD, et al. (2012) A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science 335(6066):348-353.
25. Tasciotti E, Sakamoto J, Ferrari M (2009) Conference scene: Nanotechnology and medicine: The next big thing is really small. Nanomedicine (Lond) 4(6):619-621.
26. Landis MD, Lehmann BD, Pietenpol JA, Chang JC (2013) Patient-derived breast tumor xenografts facilitating personalized cancer therapy. Breast Cancer Res 15(1):201.
27. Cerami E, et al. (2012) The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov 2(5):401-404.
28. Matthews NE, Adams MA, Maxwell LR, Gofton TE, Graham CH (2001) Nitric oxidemediated regulation of chemosensitivity in cancer cells. J Natl Cancer Inst 93(24): 1879-1885. (Pubitemid 34048655)
29. Giordano FJ (2005) Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 115(3):500-508.
30. Liao D, Corle C, Seagroves TN, Johnson RS (2007) Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res 67(2):563-572. (Pubitemid 46192193)
31. Krishnamachary B, et al. (2012) Hypoxia regulates CD44 and its variant isoforms through HIF-1α in triple negative breast cancer. PLoS ONE 7(8):e44078.
32. Subramanian A, et al. (2005) Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102(43):15545-15550. (Pubitemid 41528093)
33. Peifer M, et al. (2012) Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 44(10):1104-1110.
34. Li H, Durbin R (2009) Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25(14):1754-1760.
35. Koboldt DC, et al. (2012) VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 22(3):568-576.
36. Roma C, et al. (2013) Detection of EGFR mutations by TaqMan mutation detection assays powered by competitive allele-specific TaqMan PCR technology. Biomed Res Int 2013:385087.
37. Richter A, et al. (2013) A multisite blinded study for the detection of BRAF mutations in formalin-fixed, paraffin-embedded malignant melanoma. Sci Rep 3:1659.
38. Didelot A, et al. (2012) Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples. Exp Mol Pathol 92(3):275-280.
39. Lee A, et al. (2011) Chemotherapy response assay test and prognosis for breast cancer patients who have undergone anthracycline- and taxane-based chemotherapy. J Breast Cancer 14(4):283-288.
40. Uechi T, Tanaka T, Kenmochi N (2001) A complete map of the human ribosomal protein genes: Assignment of 80 genes to the cytogenetic map and implications for human disorders. Genomics 72(3):223-230. (Pubitemid 32281523)
41. Nadano D, Notsu T, Matsuda T, Sato T (2002) A human gene encoding a protein homologous to ribosomal protein L39 is normally expressed in the testis and derepressed in multiple cancer cells. Biochim Biophys Acta 1577(3):430-436.
42. Kuefer MU, et al. (1996) cDNA cloning, tissue distribution, and chromosomal localization of myelodysplasia/myeloid leukemia factor 2 (MLF2). Genomics 35(2):392-396. (Pubitemid 26250331)
43. Gandin V, et al. (2008) Eukaryotic initiation factor 6 is rate-limiting in translation, growth and transformation. Nature 455(7213):684-688.
44. Ray S, et al. (2013) Androgens and estrogens stimulate ribosome biogenesis in prostate and breast cancer cells in receptor dependent manner. Gene 526(1):46-53.
45. Molina H, Horn DM, Tang N, Mathivanan S, Pandey A (2007) Global proteomic profiling of phosphopeptides using electron transfer dissociation tandem mass spectrometry. Proc Natl Acad Sci USA 104(7):2199-2204. (Pubitemid 46391375)
46. Nousiainen M, Silljé HH, Sauer G, Nigg EA, Körner R (2006) Phosphoproteome analysis of the human mitotic spindle. Proc Natl Acad Sci USA 103(14):5391-5396.
47. Daub H, et al. (2008) Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell 31(3):438-448.
48. Sjoblom T, et al. (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314(5797):268-274. (Pubitemid 44571966)
49. Eyler CE, et al. (2011) Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. Cell 146(1):53-66.
50. Glynn SA, et al. (2010) Increased NOS2 predicts poor survival in estrogen receptornegative breast cancer patients. J Clin Invest 120(11):3843-3854.
51. Heddleston JM, et al. (2012) Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential. Cell Death Differ 19(3):428-439.
52. Mathieu J, et al. (2011) HIF induces human embryonic stem cell markers in cancer cells. Cancer Res 71(13):4640-4652.
53. Heddleston JM, et al. (2010) Hypoxia inducible factors in cancer stem cells. Br J Cancer 102(5):789-795.
54. Dong C, et al. (2013) Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell 23(3):316-331.
55. Burrell RA, McGranahan N, Bartek J, Swanton C (2013) The causes and consequences of genetic heterogeneity in cancer evolution. Nature 501(7467):338-345.
56. Visvader JE (2011) Cells of origin in cancer. Nature 469(7330):314-322.